An eastern cooperative oncology group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma
| Autor: | Donald L. Trump, Paul Elson, Janardan Khandakar, Robert S. Witte |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Cisplatin
Cancer Research medicine.medical_specialty Chemotherapy Bladder cancer Combination therapy business.industry Urinary system medicine.medical_treatment Urology medicine.disease Surgery chemistry.chemical_compound Trimetrexate Oncology chemistry Antifolate medicine Methotrexate business medicine.drug |
| Zdroj: | Cancer. 73:688-691 |
| ISSN: | 1097-0142 0008-543X |
| DOI: | 10.1002/1097-0142(19940201)73:3<688::aid-cncr2820730330>3.0.co;2-v |
| Popis: | BACKGROUND Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated. METHODS Ambulatory patients with advanced urothelial carcinoma were treated with the nonclassic antifol trimetrexate at the intravenous dose of 8 mg/m2 daily for 5 consecutive days every 3 weeks (4 mg/m2 daily for 5 consecutive days for patients with creatinine levels greater than 1.6 mg/dl). RESULTS Of the 48 patients in the study, one had a complete response and seven had partial responses, for an overall response rate of 17% (exact 95% confidence interval, 7-30%). The response rate in patients who had received prior methotrexate was 18%, suggesting lack of complete cross-resistance. Toxicity was manageable and primarily mucosal, gastrointestinal, and myelosuppressive. CONCLUSIONS Trimetrexate has as much activity as other single agents in advanced urothelial carcinoma. Combination therapy, possibly with cisplatin, platinum analogs, or other antifols, using trimetrexate should be studied. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text